Work Here?
Jupiter Endovascular
Work Here?
Develops and sells endovascular cardiovascular devices
Jupiter Endovascular
Work Here?
Develops and sells endovascular cardiovascular devices
Overview
Jupiter Endovascular develops and sells advanced endovascular devices to improve cardiovascular health, serving hospitals and cardiovascular clinics worldwide. Its products are catheter-based tools used in endovascular procedures, developed, cleared by regulators, and clinically validated before being sold to healthcare providers. The company differentiates itself through a strong focus on clinical affairs and product management, plus a global market presence and strategic partnerships to broaden reach while prioritizing safety and proven efficacy. Its goal is to improve patient cardiovascular outcomes by delivering reliable, clinically validated endovascular solutions to healthcare providers around the world.
About Jupiter Endovascular
Industries
Industrial & Manufacturing
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$40M
Headquarters
Menlo Park, California
Founded
N/A
Simplify's Take
What believers are saying
- Vertex Catheter received FDA 510(k) clearance on September 24, 2025, enabling commercialization.
- Oversubscribed $40M Series B led by Sonder Capital funds SPIRARE II and TFX expansion.
- Fred Ong joined as CFO to bolster finance during 2026 growth phase.
What critics are saying
- Inari Medical's FlowTriever captures 70% pulmonary embolism market share in 2024.
- SPIRARE I results at TCT 2025 show mediocre efficacy, halting SPIRARE II.
- FDA warning letter delays TFX commercialization, exhausting $40M runway in 2026.
What makes Jupiter Endovascular unique
- TFX technology shifts catheters from flexible to firm for precise pulmonary embolectomy.
- Vertex Catheter with Endoportal Control enables stable positioning in pulmonary vasculature.
- SPIRARE II trial completed enrollment for acute pulmonary embolism treatment.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$40M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
401(k) Retirement Plan
Remote Work Options
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Flexible Work Hours
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Company News
Jupiter Endovascular, a Menlo Park, CA-based medical technology startup, closed its Series B funding at over $40M
Jupiter Endovascular closed an oversubscribed Series B financing round, surpassing its $40 million target. Led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor, the funds will support the SPIRARE II clinical trial, commercialization, and new applications for its TFX technology. The Vertex Catheter with TFX recently received FDA 510(k) clearance, and SPIRARE I trial results will be presented at TCT 2025.
Jupiter Endovascular has raised over $40M in Series B funding led by Sonder Capital to advance its TFX platform and SPIRARE II trial.
Jupiter Endovascular revealed that experienced medtech finance and operations exec Fred Ong has joined the company as chief financial officer (CFO).
Jupiter Endovascular, Inc., a Menlo Park, CA-based medical technology startup, exited stealth mode with a $21M new round of financing
Jupiter Endovascular is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Jupiter Endovascular
Industries
Industrial & Manufacturing
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$40M
Headquarters
Menlo Park, California
Founded
N/A
Jupiter Endovascular is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today